CGEM
Cullinan Therapeutics, Inc.NASDAQHealthcare$14.43+3.52%ClosedMarket Cap: $873.4M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.16
P/S
0.00
EV/EBITDA
-3.38
DCF Value
$1.44
FCF Yield
-15.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-46.2%
ROA
-49.0%
ROIC
-58.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-50.7M | $-0.86 |
| FY 2025 | $0.00 | $-219.9M | $-3.72 |
| Q3 2025 | $0.00 | $-50.6M | $-0.86 |
| Q2 2025 | $0.00 | $-70.1M | $-1.19 |
Analyst Ratings
View AllWedbushOutperform
2026-03-11HC Wainwright & Co.Buy
2026-01-08WedbushOutperform
2025-12-09HC Wainwright & Co.Buy
2025-11-20HC Wainwright & Co.Buy
2025-09-12Trading Activity
Insider Trades
View AllMichaelson Jenniferofficer: Chief Scientific Officer
SellMon Mar 09
Michaelson Jenniferofficer: Chief Scientific Officer
SellMon Mar 09
Michaelson Jenniferofficer: Chief Scientific Officer
SellThu Feb 26
Michaelson Jenniferofficer: Chief Scientific Officer
SellWed Feb 25
Michaelson Jenniferofficer: Chief Scientific Officer
SellWed Feb 25
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.11
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.